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Abstract      
    
BMP2  ENHANCES  OSTEOGENESIS  OF  HUMAN  GINGIVAL  STEM  CELLS  
IN  A  PEPTIDE-­BASED  HYDROGEL    
DEGREE  DATE:  JUNE  14,  2017 Annapurna  Bondalapati,  B.D.S.  
COLLEGE  OF  DENTAL  MEDICINE  NOVA  SOUTHEASTERN  UNIVERSITY  
Directed  by:  Dr.  Uma  Devi  Kandalam,  Assistant  Professor,  Department  of  Pediatric  
Dentistry,  NSU  College  of  Dental  Medicine.    
Purpose:  The  aim  of  the  study  was  to  investigate  effect  of  the  growth  factor,  
Bone  Morphogenetic  Protein  2  (BMP2),  on  the  differentiation  of  Human  gingiva  
derived   stem   cells   (HGMSCs)   in   a   self-­assembled   three-­dimensional   (3D)  
peptide  hydrogel.  The  study  has  two  parts;;  part  1  comprised  of  optimizing  the  
dose  of  BMP2  and  Part   II  was   investigating   the  effective  delivery  method  of  
BMP2  in  enhancing  the  osteogenic  differentiation  of  HGMSCs    
Methods:  Human  gingiva  derived  mesenchymal  stem  cells  (HGMSCs)  cultured  
in  the  peptide  hydrogel  (3-­D  cultures)  were  treated  with  50,  100  and  200  ng/ml  
BMP2.  The  cells  in  the  osteogenic  differentiation  of  HGMSCs  in  the  peptide  gel  
was   evaluated   at   one   week.   The   expressions   of   osteogenic   marker   genes  
Alkaline-­Phosphatase   (ALP),   Runt   related   transcription   factor   2   (RUNX2),  
Collagen  Type  I  (COL1)  were  measured  using  quantitative  PCR.  The  results  
were   compared   with   monolayer   cells   treated   with   BMP2   (2-­D   culture).  
Furthermore,  to  evaluate  the  effective  delivery  method,  cells  were  encapsulated  
in   Puramtrix   and   BMP2   was   administered   either   in   culture   medium   or  
encapsulated   in  Puramatrix.   The   cells  were   treated   for   one  week   and   early  
osteogenic  markers  genes  were  measured.    ANOVA  was  used  to  evaluate  the  
results  and  P  <  .05  was  considered  statistically  significant.  
  viii 
Results:  The  results  of  the  study  demonstrated  a  dose  dependent  upregulation  
(P<.05)  of   the  genes   including  ALP,  RUNX2  and  COL1  at  all  concentrations  
(50,100  and  200ng/ml).  There  was  significant  up  regulation  of  gene  expression  
in   200ng/ml   compared   to   50ng/ml   (P<.05).  BMP2   treatment   accelerated   the  
mineral  deposition  in  HGMSCs.    Overall  results  of  our  study  demonstrated  that  
the  application  of  osteoconductive  agent   rhBMP2,  stimulated   the  osteogenic  
differentiation   regardless  of   the  delivery  method   that  was  used   in   this  study.  
However,   BMP2   entrapped   in   PuramatrixTM   showed   significantly   high   ALP  
expression  at  100ng/ml  compared  to  200ng/ml  concentration  
Conclusions:  The  PuramatrixTM  hydrogel  in  combination  with  BMP2  supported  
osteogenic   differentiation   of   HGMSCs.   This   novel   tissue   engineered   cell-­
scaffold  system  with  growth  factor  has  potential  for  the  regeneration  of  bone  in  
craniofacial  defects.  
      
Key  words:  Gingiva  derived  stem  cells,  Peptide  hydrogel,  Bone  
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  1 
Chapter  1  INTRODUCTION  
  
1.1  Craniofacial  Defects  
Large  size  craniofacial  defects  in  children  arise  from  many  etiologies  including  
open  skull  trauma,  infection,  congenital  anomalies  and  tumor.  Reconstruction  
of   these   large   size   defects   poses   a   reconstructive   challenge   because   of  
children’s  unique  physiology,  developing  anatomy,  and  dynamic  growth.  Over  
three-­quarters  of  all  craniofacial  defects  observed  in  the  US  per  year  are  cleft  
palates[1,   2]   (Figure   1).   The   complications   of      the   cleft   palate      include   wound  
dehiscence,   residual   lip   and/or   nose   deformity,   feeding   difficulties,   speech  
abnormalities,  dentofacial  anomalies  and  psychosocial  problems  [3]  [4]  .  
  
                                                                                    Figure  1:  Cleft  Palate  
  Current  treatment  modalities  for  management  critical  size  palatal  defects  are  limited.  
Autologous  bone  grafting  for  reconstruction  of  craniofacial  bone  is  considered  the  gold  
  2 
standard  in  pediatric  care.  The  sources  of  autograft  are  cancellous  bone  derived  from  
the  iliac  crest,  cortical  bone  from  symphysis  of  mandible,  and  cortico-­cancellous  bone  
from  the  rib  (Figure  2).  The  gold  standard  autograft  has  the  ability  to  reincorporate  into  
the  skull  (osseointegration),  lower  risk  of  material  rejection,  and  ability  to  allow  growth  
of   the   skull.      Nevertheless,   with   pediatric   patients,   additional   considerations   must  
account   for   the  high   incidence  of   bone   resorption,   the   immature  osseous   skeleton,  
limited  availability  of  bone  tissue  and  the  harvest  is  often  associated  with  undesirable  
side  effects  associated  with  donor  site  morbidity  and  repeated  surgeries.  Allografts,  on  
the  other  hand  are  accompanied  with   infections.  Recent  developments   in  stem  cell  
based  tissue  engineering  approaches  offer  an  alternative  solution.                                                                                   
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1.2  Tissue  Engineering  
Tissue   engineering   approaches   represent   a   promising   alternative   that  
would   serve   to   facilitate   bone   regeneration   even   in   large   craniofacial  
skeletal  defects.  Engineering  bone  requires  the  combination  of  osteogenic  
cells,  osteoconductive  scaffolds,  osteoinductive  growth  factors.  (Figure  3) 
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1.3  Mesenchymal  Stem  Cells  
Mesenchymal   stem   cell   based   approaches   are   promising   alternatives   to  
facilitate   bone   regeneration   in   critical   size   defects.  Mesenchymal   stem   cells  
(MSCs)  as  potential  source  for  bone  tissue  regeneration  has  been  explored  in  
recent  years  [5,  6].  MSCs  are  unspecialized  cells  which  reside  in  adult  tissues.  
They  are  highly  proliferative  with  the  intrinsic  ability  of  self-­renewal.  MSCs  have  
multipotent   differentiation   capacity   and   they   are   capable   to   differentiate   into  
multiple  cell   types   including  osteocytes,  chondrocytes,  adipocytes,   tenocytes  
and  myoblasts  [7-­9].  (Figure  4)  
  
  
Figure  4:  Differentiation  potential  of  Mesenchymal  Stem  Cells.  MSCs  can  differentiate  in  a  large  
variety  of  human  tissues  including  osteogenic,  chondrogenic,  adipogenic  and  neuronal  lineages.  
Recently,  it  was  also  demonstrated  the  presence  of  human  MSC  like  cells  in  adult  skeletal  muscle.  
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MSCs   have   high   immunomodulatory   capacity   and   inhibit   the   Major  
Histocompatibility   Complex   (MHC)-­mismatched   lymphocyte   response  
(immunogenicity).  MSCs  have  been  shown  to  express  MHC  class  I  and  other  
immune  related  molecules  as  VCAM-­1  and  LFA-­3  [10-­12].    
MSCs  can  be  obtained   from  a  wide  spectrum  of  adult   tissues  such  as  bone  
marrow,  umbilical  cord  and  orofacial  tissues  such  as  gingiva.  Bone  marrow  has  
been   a   major   source   for   the   isolation   of   MSCs   as   bone   marrow   derived  
mesenchymal  stem  cells  (BMMSCs)  have  been  proven  through  clinical   trials  
that   they   are   an   effective   treatment   for   the   osseous   defects   [13].   However,  
BMMSCs   are   highly   variable   with   limited   self-­renewal   and   differentiation  
capacity.  Furthermore,  bone  marrow  aspiration  is  known  to  be  an  invasive  and  
painful   procedure,   and   considered   as   a   complicated   procedure   for   general  
practitioners.  In  recent  years,  studies  have  explored  the  isolation  of  MSCs  from  
other   tissue  sources,   including  adipose   tissue,  umbilical   cord,  umbilical   cord  
blood  and  stem  cells  from  orofacial  region  [14].    
1.4  Orofacial  Stem  Cells:  
Recently,   isolation   of   stem   cell   populations   from   orofacial   region   has   been  
gaining  attention.  Orofacial  stem  cells  are  originated  from  neural  crest  cells  that  
can  be  differentiated  into  cartilage  and  bone  to  form  craniofacial  skeleton.  While  
autologous  BMMSCs  obtained  from  distant  part  of  the  body  far  from  craniofacial  
region  are   the   traditional  stem  cell  source   for   the   repair  and   regeneration  of  
long  bones  [15-­17];;  the  reconstruction  of  bone  in  the  craniofacial  region  showed  
partial  success  as  the  long  bones  are  originated  from  mesoderm  and  the  bones  
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in  the  craniofacial  region  are  derived  from  the  neural  crest  (ectodermal  origin).  
This  suggests  that  neural  crest  associated  cells  might  be  a  superior  cell  source  
for  the  reconstruction  of  bone  in  the  orofacial  region  as  compared  to  BMMSCs  
obtained   from   long  bones   [18].  Moreover,  orofacial  mesenchymal  stem  cells  
(OMSCs)  are  readily  accessible  from  the  oral  cavity,  can  be  easily  expanded,  
highly  proliferative  and  have  ability  to  differentiate  into  osteogenic,  odontogenic,  
adipogenic  and  neurogenic  precursor  cells.  (Figure  5)  
  
  
Figure  5:  Sources  of  adult  stem  cells  in  the  oral  and  maxillofacial  region.  BMSCs:  bone  marrow-­
derived  MSCs  from  orofacial  bone;;  DPSCs:  dental  pulp  stem  cells;;  SHED:  stem  cells  from  human  
exfoliated  deciduous  teeth;;  PDLSCs:  periodontal  ligament  stem  cells;;  DFSCs:  dental  follicle  stem  
cells;;  TGPCs:  tooth  germ  progenitor  cells;;  SCAP:  stem  cells  from  the  apical  papilla;;  OESCs:  oral  
epithelial  progenitor/stem  cells;;  GMSCs:  gingiva-­derived  MSCs,  PSCs:  periosteum-­derived  stem  
cells;;  SGSCs:  salivary  gland-­derived  stem  cells  (Reference:  Stem  Cells  in  Dentistry  –  Part  I:  Stem  
cell  sources  (Hiroshi  Egusa,  DDS,  PhD,  Wataru  Sonoyama,  DDS,  PhD,  Masahiro  Nishimura,  DDS,  
PhD,  Ikiru  Atsuta,  DDS,  PhD,  Kentaro  Akiyama,  DDS,  PhD).    
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Orofacial/dental  tissues  are  specialized  tissues  that  do  not  undergo  continuous  
remodeling  unlike   the  bone  marrow  stem  cells   [18].  As   these  stem  cells  are  
derived   from   the  neural  crest   region,  which   is  originated   from  ectoderm,   the  
dental  mesenchyme   is   often   termed  as   ‘ectomesenchyme’   due   to   its   earlier  
interaction   with   the   neural   crest.   Thus,   orofacial   stem   cells   may   possess  
different  characteristics  similar  to  those  of  neural  crest  cells  [19,  20].  Studies  
suggested   that   dental   tissue   derived   stem   cells   are   more   appealing   for  
craniofacial  application  due  to  their  increased  commitment  to  differentiate  into  
craniofacial   tissues  when  compared   to  non-­dental  derived  stem  cells.  MSCs  
derived  from  orofacial  tissue  possess  multi  differentiation  ability  and  have  the  
capacity   to   give   at   least   three   distinguishable   lineages   of   cells   including  
osteo/odontogenic,  adipogenic  and  neurogenic.  
1.5  Human  Gingival  Mesenchymal  Stem  Cells:  
Human  gingiva  is  a  well-­known  tissue  enriched  with  adult  mesenchymal  stem  
cells,  90%  of  which  originated  from  cranial  neural  crest  cells  (CNCC)  [19,  20].  
The  ectomesenchymal  origin  of  these  cell  types  exhibit  characteristics  akin  to  
those   of   neural   crest   cells.   The   neural   crest   derived   origin   makes   Human  
Gingival  Mesenchymal  Stem  Cells  (HGMSCs)  interesting  candidates  for  their  
use   in   craniofacial  bone   tissue  engineering.  GMSCs  have  shown  stem  cells  
properties  and  immunomodulatory  abilities  as  those  of  BMMSCs.  Usually  the  
gingiva   overlying   the   alveolar   ridges   and   retro   molar   region   is   frequently  
resected   during   general   dental   treatments   and   can   often   be   obtained   as   a  
discarded  biological  sample.  GMSCs  proliferate  faster  than  BMMSCs,  display  
a  stable  morphology  and  do  not  lose  their  MSC  characteristics  with  extended  
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passaging   [21]   and   differentiate   into   various   lineages,   when   cultured   in  
appropriate  inductive  media  [22-­26].  The  distinctive  feature  of  GMSCs  is  that,  
they   display   potent   immunosuppressive   and   anti-­   inflammatory   functions.  
Recently,  the  mechanisms  of  the  immunomodulatory  effect  of  human  GMSCs  
on  the  innate  immune  cells  have  been  investigated  [20].    
MSCs  derived   from  human  gingiva   (HGMSCs)   can   readily   be  obtained  with  
technique  minimally   invasive  methods   and   can  maintained/preserved   under  
standard   laboratory   conditions   (Figure   6).   Being   derived   from   neural   crest,  
HGMSCs  offer  distinctive  advantages   for  craniofacial  bone-­tissue   repair  and  
regeneration.    
  
                                                                  Figure  6:    Human  Gingival  Tissue  
1.6  Scaffold  
A   right   combination   of   cells-­scaffold   and   growth   factors   is   essential   for  
regeneration.  Hydrogel  scaffolds  are  able  to  mimic  natural  extracellular  matrix  
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of  many  tissues  and  are  able  to  form  solid  constructs  that  permit  homogenous  
distribution  of  the  cell.  Hydrogels  offer  the  convenience  of  incorporating  growth  
factors  and  cells  prior  to  injection  into  the  in  vivo  site  to  enable  gel  formation.  
Injectable  hydrogels  present  a  novel  approach  of  local  delivery  of  stem  cells  in  
tissue   engineering   applications,   enabling   surgeons   to   transplant   cells   in   a  
minimally  invasive  way.  They  are  naturally  biocompatible,  as  they  do  not  cause  
an   immune   response  or   inflammatory   reaction.  These  gels  are  degraded  by  
hydrolysis,   action   of   enzymes   and/or   dissolution.   The   use   of   injectable  
hydrogels  has  been   tested   for  bone   tissue  engineering.   Injectable  hydrogels  
are  novel  strategy  for  local  delivery  of  stem  cells  as  they  can  fill  irregular  shapes  
and  voids  in  the  bone  defects  to  and  maximizes  cell  adhesion  and  interaction  
enhancing  bone  regeneration  [27].    
Self-­assembled   short   peptide   scaffolds   are   new   class   of   hydrogels,   with  
implantable  or  injectable  mode  of  delivery  of  the  cells  as  well  as  growth  factors.  
The  nanofiber   structures  of   these  peptides   (<10nm   in  diameter)   are   several  
times   thinner   than   the   cells,   which   permits   them   to   surround   the   cells   in   a  
manner  similar  to  the  natural  extracellular  matrix.    
Self-­  assembling  peptides  have  ability  to  form  stable  hydrogels  and  have  been  
used   in-­vivo   animal   studies   for   repairing   bony   defects.   In   particular,   liquid  
hydrogel  can  fill  the  three  dimensional  (3D)  irregular  defects  in  the  craniofacial  
region  and  assists   in  enhanced  healing  without  forming  a  scar.  Furthermore,  
these  3D  scaffolds  mimic  the  defect  while  being  rigid  enough  to  support  cells  
and  flexible   to  blend   into  host   tissue.  3D  scaffolds   increase  cell  proliferation,  
migration  and  viability  compared  to  preformed  2D  scaffolds.  Our  study  intends  
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to  use  a  3D  peptide  based  hydrogel  biomaterial,  PuramatrixTM,  with  over  99%  
water  content  that  can  self-­  assemble  into  3D  interweaving  nanofibres    
  
1.7  PuramatrixTM  
PuramatrixTM  is  a  chemically  defined  hydrogel,  devoid  of  any  proteins  of  animal  
origin  and  has  ability  to  carry,  deliver  the  cells  on  to  the  defect  site  (Figure  7).  
It   can   mimic   natural   extracellular   matrix   and   present   a   novel   approach   for  
delivery  of  stem  cells  with  ease.  Additionally,  it  acts  as  a  dynamic  liquid  support  
to  carry  living  cells,  drugs  and  growth  factors  and  have  the  ability  to  deliver  cells  
at  the  defect  site  without  inflammatory  reaction  with  minimal  immune  response  
and   reduce   scar   formation[28,   29].   Nanostructured   biomaterials   are   gaining  
popularity   in   regenerative  medicine  because   they  mimic  natural  extracellular  
matrix  in  a  nano  scale.  Physical  and  biological  parameters  of  this  scaffold  can  
be  modified  due  to  its  synthetic  nature.  Bioactive  modifications  can  be  made,  
which  makes  it  versatile  in  terms  of  cell  adhesion  while  increasing  its  stability.  
PuraMatrixTM  hydrogel   is  capable  of  both   ionic  and  hydrophobic   interactions.  
These   interactions   trigger   spontaneous   self-­assembly   enabling   cell  
encapsulation  and  filling  in  both  in  vitro  and  in  vivo  applications.  We  intend  to  
utilize   this  property   to  encapsulate  HGMSCs  within   the  PuraMatrixTM   for   the  


















        Figure  7:    PuramatrixTM  –  Self  assembled  peptide  scaffold  (Figure  showing  its  injectability)  
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                                                                                    Table  1:  Characteristics  of  Puramatrix  
1.8  Growth  Factor  
In  bone  tissue  engineering,  in  concert  with  osteoprogenitor  cells  and  scaffolds,  
a   plethora   of   growth   factors   enhance   osteogenesis.   Growth   factors   are  
particularly   interesting   because   of   their   ability   to   target   specific   cellular  
receptors  and  actively  trigger  various  cellular  signaling  processes  [30].  Major  
players   in   the   skeletal   tissue   engineering   are   members   of   the   TGFβ  
superfamily,  notably  the  members  of  bone  morphogenetic  protein  superfamily  
(BMPs).        
1.9  Bone  morphogenetic  Proteins  
Bone   morphogenetic   proteins   are   a   family   of   osteoinductive   proteins   that  
promote   differentiation   of   mesenchymal   cells   into   osteoblasts   and   promote  
neovascularization.  Among   the  15   identified  BMPs,  BMP-­2  and  BMP-­7   (i.e.,  
osteogenic   protein-­1)   are   now   commercially   available   and   have   been  
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investigated   as   an   alternative   to   bone   auto   grafting   in   a   variety   of   clinical  
situations,   including  spinal   fusions,   internal   fixation  of   fractures,   treatment  of  
bone  defects,  and  reconstruction  of  maxillofacial  conditions.   
Bone  morphogenetic  protein-­2  (BMP-­2)   is  currently  the  one  of  the  only  Food  
and  Drug  Administration  (FDA)-­approved  osteoinductive  growth  factor  used  as  
a  bone  graft  substitute.    BMP2  successfully  induced  osteoblastic  differentiation  
of  mesenchymal   stem   cells   [31].  While   BMP2,   conventionally   used   in   large  
quantities  (as  high  as  10 µg/mL),  in   invivo  applications,  have  adverse  effects  
such   as   enhanced   bone   formation   in   undesired   site,   inflammation   and  
respiratory  distress  [32].  Furthermore,  In  vitro  studies  report  using  wide  range  
of  doses  of  BMP2  (100-­1000ng/ml).    However,  optimal  dose  of  BMP2  may  differ  
with  the  type  of  stem  cells  and  the  scaffolds  employed.  Our  previous  studies  
demonstrated  that  concentration  range  from  50ng/ml  to  200ng/ml  BMP2  could  
induce  osteogenic  differentiation  of  HGMSCs  [33]    in  monolayer  cultures.  In  this  
project,  we  intend  to  establish  optimal  dose  of  BMP2  in  HGMSCs  encapsulated  
in  PuramatrixTM  hydrogel.  
Another  major  limitation  of  clinical  BMP-­2  treatments  is  the  rapid  diffusion  from  
the  implant  site,  causing  a  significant  decrease  in  local  concentration,  as  well  
as  rapid  loss  of  bioactivity  in  the  soluble  form.  Soluble  or  free  BMP-­2  quickly  
loses   bioactivity   due   to   proteolytic   degradation   and   denaturing   caused   by  
physiologic   conditions   (i.e.   pH,   temperature,   salt   concentration).   Therefore,  
recent  efforts  have  focused  on  encapsulating  the  BMP  molecule  to  protect   it  
from   degradation   or   enhancing   the   binding   affinity   of   BMPs   to   the   carrier  
material  [34].  Matrix  based  systems  for  growth  factor  delivery  for  regenerating  
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the   tissue   provides   controlled   release   and   stabilizes   the   loaded   signaling  
molecule.   However,   limited   studies   have   established   on   the   mode   of   the  
delivery   of   growth   factor   and   their   effect   on   osteogenic   differentiation   on  
mesenchymal  stem  cells.  In  this  study,  we  intend  to  test  and  compare  two  types  
of   delivery   methods   to   establish   the   suitable   method   of   delivery   that   can  
enhance  osteogenic  differentiation  of  HGMSCs  encapsulated  in  PuramatrixTM.  
1.10  Innovation:    
The  current  surgical  protocol  for  repair  of  critical  size  defects  in  the  craniofacial  
region  require  the  gold  standard  autografts.  Cell  based  tissue  engineering  aims  
to   replace   or   facilitate   the   repair   and   regeneration   of   damaged   tissue   by  
applying   the   combinations   of   biomaterials,   cells,   and   bioactive   molecules  
(growth  factors).  Growth  factors  play  a  crucial  role  in  harnessing  and  controlling  
tissue   regeneration.  A  primary  goal  of  growth   factor  delivery   for  bone   tissue  
engineering  is  to  accelerate  healing  and  enhance  bone  formation.  Additionally,  
the   dose   of   BMP2   remains   crucial   in   bone   tissue   engineering   applications.  
Currently  supra-­physiological  dose  has  been  used  which  is  resulting  in  adverse  
effect.  It  is  essential  to  optimize  the  dose.  Another  aspect  of  the  use  of  growth  
factors  in  tissue  engineering  is  controlled  delivery.    The  conventional  methods  
of  administering  BMP2  in  the  culture  medium  might  be  homogeneous,  however,  
in   this   method   only   small   amount   reaches   to   the   cells   related   to   biological  
signaling  pathways.  In  contrast,  the  availability  of  growth  factor  in  direct  contact  
with  cells  might  be  an  efficient  way  of  delivering.    The  effect  of  delivery  mode  
on  osteogenic  differentiation  of  HGMSCs  have  never  been  tested.  Hence  in  this  
study   we   intend   to   investigate   the   dose   and   delivery   strategy   of   BMP2   on  
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HGMSCs  encapsulated  in  the  PuramatrixTM,  a  new  biomaterial  that  serves  as  
synthetic  extracellular  matrix.  Overall  goal  of  this  study  was  to  assess  the  effect  
of  BMP2  on  osteogenic  differentiation  of  PuraMatrixTM  encapsulated  HGMSCs.    
1.11  Objectives    
The  long-­term  goal  of  this  project  is  to  develop  a  3D  injectable  scaffold  for  the  
purpose  of  bone  regeneration  in  patients  with  cleft  lip  and  palate  defects  using  
HGMSCs  and  minimal  dose  of  BMP2.    
The  objective  of   this  study  was   to  assess   the  effect  of  BMP2  on  osteogenic  
differentiation   of   PuraMatrixTM   encapsulated   HGMSCs.   This   study   has   two  
specific  aims  
1.12  Specific  aims   	 
Specific   aim   1a)   is   to   assess   optimal   dose   of   BMP-­2   on   osteogenic  
differentiation  of  PM  encapsulated  HGMSCs.    
Different   doses   (50,100   and   200ng/ml)   of   BMP2   will   be   administered   to  
HGMSCs  in  monolayer  cultures  (2-­D)  as  well  as  PuramatrixTM    encapsulated  
HGMSCs   (3-­D)   cultures   for   one   week   and   the   osteogenic   maker   gene  
expressions  were  measured.  
Specific  aim  1b)  is  to  examine  and  compare  BMP2  delivery  strategies  that  
enhance  the  osteogenic  differentiation  of  HGMSCs  
The  two  types  of  delivery  methods  include  
1.   HGMSCs   stimulation   with   soluble   BMP2:   The   HGMSCs   will   be  
encapsulated   in   PuramatrixTM   and   BMP2   will   be   supplemented   with  
osteogenic  medium  at   regular   intervals   for   one  week   and   osteogenic  
  16 
differentiation   will   be   investigated   by   measuring   osteogenic   markers  
gene  expression.  
2.   HGMSCs  stimulation  with  adsorbable  method:      HGMSCs  loaded  with  
BMP2   will   be   encapsulated   in   PuramatrixTM   will   be   induced   with  
osteogenic  medium  for  one  week  and  the  osteogenic  differentiation  will  
be  examined  by  measuring  the  osteogenic  marker  gene  profiles.        
  This   cell-­scaffold   -­growth   factor   composite   will   have   potentially   therapeutic  
benefit  for  the  repair  of  bony  defects.  
1.13  Hypothesis    
In  this  study,  we  would  like  to  test  these  two  hypothesis  
1.   The   optimal   concentration   of   BMP2   that   can   trigger   the   osteogenic  
differentiation  
2.   Whether   Puramatrix   encapsulated   BMP2   can   enhance   osteogenic  
differentiation  of  HGMSCs,  if  so  whether  the  mode  of  delivery  method  
influences  on  the  osteogenic  differentiation  of  HGMSCs.      
Null  Hypothesis:  
1.  Mode  of  BMP2  delivery  does  not  influence  the  osteogenic  differentiation  of  
HGMSCs  
2:  Concentration  of  BMP-­2  has  no  effect  on  osteogenic  differentiation  of  PM  
encapsulated  HGMSCs.  
Alternative  Hypothesis:  
1.   Mode   of   BMP2   delivery   may   influence   the   osteogenic   differentiation   of  
HGMSCs  
2:  Concentration  of  BMP-­2  has  an  impact  on  osteogenic  differentiation  of  PM  
encapsulated  HGCMSCs.  
  17 
CHAPTER  2  MATERIALS  AND  METHODS  
2.1  Materials  
Commercially  available  PuraMatrixTM  hydrogel  BD  Biosciences,  San  Jose,  CA)  
was  used   for   the  study.  Mesenchymal  stem  cell  medium  was  obtained   from  
Sciencell   (Carlsbad,   CA).   Commercially   available   rhBMP2   (R&D   systems,  
Minneapolis,  MN)  was  used.  All  other  necessary  chemicals  and   lab  supplies  
were  obtained  from  Sigma  (St.  Louis,  MO)  and  VWR  international  (Atlanta,  GA),  
respectively.   
2.2  Overall  Study  Design:  
Human   gingival   tissue   was   obtained   upon   approval   of   Institutional   Review  
Board.      HGMSCs   were   isolated   using   enzymatic   digestion   method.   Cells  
isolated   from   the   tissue  were  cultured  and  expanded  under  standard  culture  
conditions.   Cells   at   70-­80%   confluency   were   induced   with   osteogenic  
supplements   and   osteogenic   differentiation   of   HGMSCs  was   determined   by  
gene  expression  of   various  osteogenic  differentiation  marker  genes.  Mineral  
deposition  of  osteogenically  induced  cells  was  confirmed  by  Alizarin  Red  and  
Von  Kossa  staining  techniques.  Cells  were  encapsulated  in  3D  PuraMatrixTM    
scaffold  and  then  supplied  with  CM  in  one  group  and  OM  in  other  group.  Cells  
were   encapsulated   in   PuraMatrixTM   in   different   cell   concentrations   (1x104,  
2x104   4x104   and   8x104   cells/ml).   Cell   proliferation   was   assessed   by   WST  
assay.  Cells  were  encapsulated  in  PuraMatrixTM  with  different  concentrations  
of  BMP2  (50ng/ml,  100ng/ml,  200ng/ml)  for  1  week.  Cells  grown  in  osteogenic  
medium  served  as  a  control.  Osteogenesis  was  determined  by  gene  expression  
studies,  mineralization  studies  and  ALP  assay.   
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Specific  Aim  1a:  
  
  
Figure  8:  Specific  Aim  1a:  To  assess  optimal  dose  of  BMP2  on  osteogenic  differentiation  
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Specific  Aim  1b:  
  
  
Figure  9:  Specific  Aim  1b:  Examine  and  compare  BMP2  delivery  strategies  that  enhance  
osteogenic  differentiation  of  HGMSCs  
     
2.3  Isolation  of  gingival  stem  cells  and  Cell  culture  
Gingival   tissue   was   obtained   upon   approval   of   Institutional   Review   Board.  
Mesenchymal  stem  cells  were  isolated  from  the  gingival  tissue  using  standard  
procedures.    
2.3.1  Enzymatic  Digestion  
Briefly,   the  gingival   tissue  was  minced   thoroughly   to  make   to   smaller   tissue  
samples  and  were  digested  enzymatically  using  1mg/ml  collagenase  and  0.2%  
dispase  for  15  minutes.  The  first  cell  suspension  was  discarded  to  avoid  the  
interference  of  epithelial  cells.  The  tissue  samples  were  further  digested  with  
1mg/ml  collagenase  and  0.2%  dispase  and   the  cell  suspension  was  pooled.  
The  cell  suspensions  were  centrifuged  and  the  cell  pellet  were  plated  in  tissue  
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culture   flask   and   grown   under   standard   culture   conditions,   in   a   humidified  
incubator  at  37°C  and  5%  CO2.  
2.4  Cell  Culture:  
The   cells   were   cultured   in   growth   medium   (DMEM,   10%   FBS   and   1%  
antibiotics)  at  37°C  and  5%  CO2.  To  ensure  uniform  cell   population   first   two  
passage   cells   were   kept   further   expansion   and   cells   from   third   or   fourth  
passage  were  used  for  all  studies.    
2.5   Characterization   of   HGMSCs   surface   markers   by   flow   cytometry  
method    
Monolayer   cells   (1x106  per  group)  were  used   to  detect   the   surface  markers  
using   Miltenyi   Kit   per   manufacturer’s   instructions   using   a   flow   cytometer  
FACAria  IIIu  (BD  Biosciences,  San  Jose,  CA).    The  specific  markers  positive  
for   mesenchymal   stem   CD73,   CD90,   CD105,   and   negative   for   CD34   were  
measured  at  the  facilities  at  University  of  Miami  using  a  fluorescent  activated  
cell   sorter   FACAria   IIIu   (BD   Biosciences,   San   Jose,   CA)   with   adjusted  
florescence  compensation  setting.  Negative  samples  were  used  to  set  up  the  
thresholds  of  quadrant  markers   
2.6   HGMSCs   encapsulation   and   culture   in   PuramatrixTM   (cell–gel  
constructs  3D  culture)  
  The  cells  (HGMSCs)  from  3rd  or  4th  passage  was  used  for  all  of  experiments.  
Based  on  our  pilot  studies  we  have  chosen  to  use  0.5%  PuramatrixTM  for  all  the  
experiments.   The   encapsulation   method   was   followed   per   manufacturer’s  
instructions.  Briefly,  the  cells  in  10%  sucrose  solution  were  mixed  in  250µL  of  
Puramatrix   solution  at   1:1   ratio   and   the   cells   suspended   in   the  gel   (2   x   106  
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cells/gel)  were  slowly  released  into  the  growth  medium.  After  30  minutes  of  the  
incubation  at  37ᵒC  the  growth  medium  was  replaced  to  and  cells  were  fed  with  
new  growth  medium  and  gelation  was  examined  under  microscope.  The  cell-­
gel  constructs  were  finally  incubated  at  37ᵒC,  5%  CO2.The  cell-­gel  constructs  
were  further  incubated  under  standard  culture  conditions  and  cell  morphology  
was  monitored  under  phase  contrast  microscope  on  daily  basis.    
2.7  BMP2  Treatment:    
After   two   days   of   the   encapsulation,   the   culture   medium   was   replaced   by  
osteogenic   medium   (culture   medium   +   50µg/ml   Ascorbic   acid,   β-­
Glycerophosphate   Dexamethasone).   Cell-­scaffold   inserts   placed   in   12   well  
plate  provided  with  osteogenic  medium.  The  medium  was  replenished  twice  a  
week.  The  cell-­gel  construct  supplemented  with  osteogenic  medium  considered  
as  control  group.  The  experimental  groups  were  supplemented  with  increasing  
concentrations  of  BMP2  (50ng/ml,  100ng/ml  and  200ng/ml).  Experiments  were  
performed   to   measure   alkaline   phosphatase   enzyme   activity,   osteogenic  
marker  gene  expression  and  mineralization.  All  experiments  were  repeated  five  
times.  Detailed  experimental  procedure  is  given  below.  
2.8  Cell  Proliferation  Assay  (WST  Assay)  
Two  types  of  assays  were  planned  in  this  experiment.  To  determine  the  effect  
of   BMP2   on   HGMSCs   proliferation,   and   to   examine   whether   Puramatrix   TM  
could  support  the  cell  proliferation.    
2.8.1  BMP2  treatment  to  HGMSCs  
The  cells  seeded  in  96  well  plate  (10,000  cells/  per  well)  were  allowed  to  attach  
overnight   and   subsequently   induced   with   various   concentrations   of  
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BMP2(50,100   and   200ng/ml)   and   grown   for   1,2   and   3   days.   The   cell  
proliferation  WST  assay  was  performed  after  designated  time  points.      
2.8.2  HGMSCs  in  Puramatrix  Gel  
Cells  incubated  for  designated  period  (1,  2  and  3  days),  were  WST-­1  reagent  
was  added  to  the  cells  cultured  in  growth  medium  to  1:10  final  concentration.    
The   assay   was   conducted   at   24,   48   and   72   hours’   time   intervals   and   the  
absorbance  was  measured  using  micro-­plate  reader.    
  
                                                                                                        Figure  10:  WST  Assay  
2.9  Gene  expression  by  quantitative  PCR    
Briefly,  the  cells  were  released  from  the  gel  by  mechanical  disruption  and  RNA  
was   extracted   using   Trizol   (Life   Technologies,   Carlsbad,   CA)   method   per  
manufacturer’s  instruction.  RNA  was  quantified  and  cDNA  was  measured  using  
to   standard   protocols.   Osteogenic   marker   genes   ALP,   Collagen   type   I   and  
Runt-­related   transcription   factor  2   (RUNX2)  expression  were  assessed  after  
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one  week  using  Quantitative  PCR  (Step–One  plus  Applied  Biosystems,  Foster  
City,  CA).  Expression  levels  were  determined  by  using      2-­ΔΔCt  methods  
  
  2.9.1  Osteogenic  marker  gene  expression  of  HGMSCs  treated  with  BMP2:  
The  effect  of  BMP2  on  HGMSCs  monolayer  cultures  and  cells  embedded   in  
Puramatrix  was  examined  for  their  osteogenic  differentiation.  The  cells  at  70  to  
80%   confluency   was   replaced   with   osteogenic   differentiation   medium  
(DMEM,10%  FBS,  antibiotic  and  antimicrotic  reagent,  50µg/ml  ascorbic  acid,  
β-­glycerophosphate  and  dexamethasone  induced  with  different  concentrations  
of  BMP2  (50,100  and  200µg/ml).  The  cells  without  BMP2  were  designated  as  
control.   The   gene   expression   of   osteogenic   markers   genes   was   measured  
using  quantitative  PCR  method.  
2.9.2   Osteogenic  markers   gene   expressions   of   HGMSCs   embedded   in  
Puramatrix  treated  with  BMP2  
  From  the  data  that  was  obtained  from  cell  viability  experiments,  the  cell  density  
to  embed  in  the  PuramatrixTM  was  determined.  The  cells  at  2  x  106  cells  were  
mixed  in  250µL  of  PuramatrixTM  solution  and  the  cell-­scaffold  insert  was  placed  
in  the  each  well  of  a  12-­well  culture  plate  and  allowed  to  solidify.  After  two  days,  
the  culture  medium  will  be  replaced  by  osteogenic  medium  (control  group).  The  
experimental   groups   were   supplemented   with   increasing   concentrations   of  
BMP2  (50ng/ml,  100ng/ml  and  200ng/ml).  The  medium  was  replenished  twice  
a  week  for  both  control  group  and  experimental  group.  
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2.10   Gene   expression   studies   of   PuramatrixTM   encapsulated   HGMSCs  
with  BMP2     
In   order   to   determine   the   osteogenic   differentiation   of   PuramatrixTM  
encapsulated   BMP2,   different   concentrations   of   BMP2   (50,   100,  
200ng/ml)  were  loaded  along  with  HGMSCs  on  to  PuramatrixTM  and  cells  were  
differentiated  in  osteogenic  medium.  The  cells  with  osteogenic  medium  with  out  
BMP2  were  considered  as  control   
  
  
                                                                                                        Figure  11:  Gene  Expression  studies  
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  2.11  Mineralization  
Cells  cultured  in  growth  medium  and  osteogenic  medium  were  grown  for  3  to  4  
weeks  and   in  vitro  mineralization  was  conducted.  The  detailed  experimental  
design  is  given  below.  
2.11.1  Alizarin  Red  Staining    
Determination  of  calcium  deposits  were  detected  to  the  constructs  grown  at  21-­
day   time.  The  cells  were  stained  with  2%   filtered  Alizarin  Red  stain   (Sigma-­
Aldrich,  St  Louis,  MO)  for  ten  minutes  to  detect  the  calcium  deposits.  Calcium  
deposits  appeared  as  orange  color  stain  in  the  section.    
2.11.2  Von  Kossa  Staining    
To   determine   the   presence   of   phosphate   based   mineral,   cells   stained   by  
applying   2%   silver   nitrate   (Sigma-­Aldrich,   St   Louis,  MO)   solution   for   1   hour  
under  bright  light.  The  reaction  was  stopped  by  adding  the  developing  solution,  
viz.   1%   sodium   thiosulphate   (Sigma-­Aldrich,   St   Louis,   MO)   for   1   min   and  
observed  under  phase  contrast  microscope  (Olympus,  XI  50)  
2.12  Statistical  analysis  
Following  the  guidelines  from  Cohen  [31],  for  a  power  of  0.8,  and  alpha  of  0.05  
and  for  an  independent  test  of  two  means  a  samples  from  no  less  than  6  donors  
will  be  employed.  Thus,  total  6  biological  replicates  and  2  technical  replicates  
for  the  sample  obtained  from  each  donor.  To  evaluate  differences  between  or  
among  groups,  analysis  of  variance  (ANOVA)  was  performed.  A  P-­value  <  0.05  
is  selected  for  significance  of  the  statistical  tests.  
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CHAPTER  3  RESULTS:  
3.1  Isolation  and  culture  of  human  gingival  stem  cells:  
The  cells  isolated  from  the  tissue  were  seeded  at  a  density  of  2  x  104  cells/cm2  
and   fed  with   growth  medium   (DMEM  supplemented  with   10%  FBS  and   1%  
antibiotics).     The  cells  reached  70  to  80%  confluency  after  7   to  8  days’  post  
seeding.  The  cell  population  was  homogenous;;  cells  were  tightly  adhered  with  
spindle-­shaped  cells  (Figure  12)  
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3.2  Flow  cytometry  analysis  
The   flow  cytometry   results  confirmed  positive   for  CD  73,  CD  90,  CD105   (all  
above  90%)  and  negative  for  hematopoietic  stem  cell  marker  CD  34  (Figure  13)  
  
  
Figure  13:  Flow  Cytometry  data  showing  surface  markers  of  mesenchymal  stem  cells.  The  cells  
showed  over  90%  positive  to  CD  73,  CD  90,  CD  105  and  negative  to  CD  34  
  
  
3.3  Cell  Growth  in  PuraMatrixTM  (cell–gel  constructs  3D  model)    
For  all  our  studies  cells  from  passage  3  or  4  were  used.  Cell  morphology  and  
growth   characteristics   were   monitored   sequentially   under   light   microscope.  
Under   phase   contrast   view,   HGMSCs   seeded   on   to   the   PuraMatrixTM   nano  
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scaffolds  showed  spherical  structures  at  Day  0.  Cell  growth  was  observed  from  
day1.  On  Day  5,  the  cells  attained  their  original  spindle  shaped.  Morphological  
Observation   of   cells   encapsulated   in   Puramatrix   showed   interconnections  
between  the  cells.  (Figure  14).    
  
Figure  14:  Human  gingival  stem  cells  encapsulated  in  PuramatrixTM.  The  cell  morphology  
showed  spindle  shaped  cells  
  
3.4.1  Proliferation  of  HGMSCs  induced  in  BMP2    
WST  assay  is  a  quantitative  assay  to  measure  the  cell  proliferation.  Based  on  
our  pilot  studies,  the  BMP2  doses  were  determined.  The  cell  viability  has  not  
decreased   at   any   concentration   that   we   selected.   There   was   a   significant  
increase  in  the  cell  number  was  observed  at  all  concentration  from  day  2.  There  
was  significant  increase  in  the  cell  number  at  all  concentrations  on  day  2  and  
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day  3  (Figure  15).  Thus  we  determined  that  the  doses  we  used  will  not  inhibit  
the  cell  proliferation.  
  
                                                                                                                        Figure  15:  Cell  Proliferation  in  BMP2  
3.4.2  HGMSCs  encapsulated  in  PuramatrixTM:  Cell  Proliferation     
The  cells  seeded  at  0.1  million,  1  million,  0.3  million  and  3  million  cells  per  ml.  
The  cell  proliferation  was  observed  at  1,  2  and  3  days.  Our  results  revealed  that  
there  was  slight  increase  in  the  cell  number  within  the  group  from  day  1  to  day  
3.  There  was  significant  increase  in  cell  proliferation  at  the  density  of  300,000  
on  day  3  (Figure  16).  
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                                                                                                      Figure  16:  Cell  Proliferation  in  Puramatrix  
3.5  Gene  expression  studies:  
Gene  expression  of  various  genes  have  been  investigated  at  day  7.    The  effect  
of   BMP2   was   compared   to   monolayer   cultures   (2-­   D)   cultures   with   the  
PuramatrixTM  encapsulated  HGMSCs  (3-­D  cultures).  The  ALP  gene  expression  
upregulated  by  40,  80,  and  150%   in  3-­D  cultures  compared   to  2-­D  cultures.  
Although  there  was  significant  increase  in  ALP  gene  expression  compared  to  
control   group,   there   was   no   significant   difference   among   the   experimental  
group   in   2-­D   cultures.   On   the   other   hand,   the   ALP   gene   expression   has  
significantly   increased   (P<0.05)   in   cells   induced  with   200ng/ml  BMP2  group  
compared   to   50ng/ml   in   3-­D   cultures   (Figures   17,   18).   Dose   dependent  
upregulation  has  been  observed  in  ALP,  Col  I  and  RUNX2.  Nevertheless,  the  
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expression  of  Collagen  Type  I  and  RUNX2  genes  expressed  similar  manner  in  
cells  cultured  in  2-­D  environment  as  well  as  3-­D  cultures.  (Figures  19,  20,  21,  
22)  
  
                        Figure  17:    Relative  Gene  Expression  of  Alkaline  Phosphatase–  2D  Culture  (1week)                                                                          
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                                      Figure  19:  Relative  gene  Expression  of  Type  1  Collagen  –  2D  Culture  (1week)  
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                                                    Figure  21:  Relative  Gene  Expression  of  RunX2  –  2D  Culture  (1week)  
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Specific   Aim   1b:   Different   delivery   strategies   of   BMP2   effect   on   HGMSCs  
osteogenic  differentiation  –    
BMP2   induced  osteogenic  differentiation  of  HGMSCs:  Two   types  of  delivery  
methods   were   compared   in   this   study   (Figure   9).   1)   The   HGMSCS   were  
encapsulated   in   PuramatrixTM   and   BMP2   was   administered   in   the   culture  
medium   (soluble   method).   2)   The   HGMSCs   and   BMP2   were   encapsulated  
together  in  Puramatrix  (adsorbable  method)  
The  results  of  the  study  demonstrated  that  the  application  of  osteoconductive  
agent   rhBMP2,   stimulated   the   osteogenic   differentiation   regardless   of   the  
delivery  method   that   was   used   in   this   study.   However,   BMP2   entrapped   in  
PuramatrixTM  showed  significantly  high  ALP  expression  at  100ng/ml  compared  
to  200ng/ml  concentration  (Figure  23,  24,  25)  
  
  
    Figure   23:  Relative   Gene   Expression   of   ALP   for   the   cells   treated   with   or   without   osteogenic  
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Figure   24:   Relative   Gene   Expression   of   Type   1   Collagen   for   the   cells   treated   with   or   without  
osteogenic  differentiation  medium  for  one  week  
  
  Figure  25:  Relative  Gene  Expression  of  RUNX2  for  the  cells  treated  with  or  without  osteogenic  
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3.6  Mineralization:  
Monolayer   culture   and   3D   Culture   of   HGMSCs   were   induced   with   different  
concentrations   of   BMP2   supplemented   with   osteogenic   medium.   HGMSCs  
induced  with  OM  showed  enhanced  mineral  depositon  after  35  days.  In  BMP2  
induced  cells  within  3  weeks  enhanced  mineral  deposition  was  observed.    The  
cells  showed  positive   for  Alizarin  red  and  Vonkossa  stains.  BMP2  enhanced  
the  cell  differentiation  (Figure  26,  27)    
 
Figure  26:  Mineralization  2D  Culture  –  Alizarin  Red  and  Von  Kossa  stain  
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CHAPTER  4  DISCUSSION  AND  CONCLUSIONS  
4.1  Discussion:  
Cell  based  bone  tissue  engineering  approaches  are  governed  by  the  successful  
use  of  stem  cells,  several  signaling  molecules  and  osteo-­conductive  scaffolds. 
Two  main  approaches  are  mainly  utilized  to  develop  engineered  tissue;;  
1)  utilizing  the  scaffold  as  extracellular  matrix  to  support  stem  cell  growth  and  
migration   and   2)   scaffold-­based   delivery   of   signaling   molecules   (growth  
factors).    
In   this   study   a   self-­assembling   hydrogel   scaffold,   PuramtrixTM,   was   used   to  
deliver  stem  cells.  Our  study  demonstrated  that  PuramatrixTM  supported  the  cell  
growth   at   all   concentrations   tested   providing   adequate   niche   for   the   cell  
survival.  The  data  from  our  study  suggested  that  PuramatrixTM  can  support  the  
growth  of  3x106  per/ml  cells  without  causing  any  toxic  effect.    Our  results  are  in  
agreement  with   a   previous   study  by  Cavalacanti   et   al   [35].  However,   in   our  
study,  the  cells  up  to  3  million  survived  during  the  entire  experimental  period  
where  as  in  Cavalacanti  et  al’s  study;;  there  was  a  decrease  in  cell  number,  that  
were  encapsulated  above  800,000  cell  per  ml.  This  difference  in  the  percent  
survival  could  be  due  to  the  concentration  of  the  gel  and  the  type  of  the  cells  
that  was  used.  We  further  investigated  the  effect  of  growth  factor  on  HGMSCs  
proliferation  and  differentiation.    
Owing  to  the  critical  role  of  growth  factors  in  controlling  basic  cellular  functions,  
and   their   ability   to   directly   elicit   and  orchestrate   tissue   regeneration,   a  wide  
range   of   growth   factors   has   been   tested   for   regeneration   of   bone.      Bone  
morphogenetic  proteins  (BMPs)  are  frequently  used  growth  factors,  which  play  
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essential  role  in  skeletal  development,  bone  formation  and  mesenchymal  stem  
cell  (MSC)  differentiation  [36].  The  BMP  signaling  pathway  plays  many  crucial  
roles  in  bone  formation  and  is  involved  in  multiple  stages  of  the  developmental  
process,   including   osteoblast   differentiation,   mesoderm   patterning,   bone  
formation,  and  craniofacial  development  [37].  They  elicit  new  bone  formation  in  
ectopic  and  orthotopic  sites.  Of  these  most  commonly  used  is  BMP2.  However,  
BMP2   is   labile   and   expensive   and   the   over   dose   of   BMP2   might   cause  
deleterious  effects  especially  when  used  in  pediatric  population.  Keeping  in  the  
view   of   its   use   in   pediatric   population,   in   this   study   two   aspects   have   been  
proposed.  1)   to  establish   the  optimal  dose  of  BMP2  2)  whether   the  mode  of  
delivery   of   BMP2   can   influence   the   osteogenic   potential   of   HGMSCs.  
PuramatrixTM,  a  hydrogel  scaffold  was  used  to  deliver  stem  cells  and  BMP2.  
The  effect  of  BMP2  on  HGMSCs  proliferation  was  investigated  on  monolayer  
cultures.  Although  BMP2  is  known  to  promote  the  differentiation  of  cells  into  the  
osteoblast   lineage,   none   of   the   concentrations   that   were   used   in   our   study  
inhibited   the   cell   proliferation.   Our   results   are   in   agreement   with   previous  
reports  [38,  39].  
In  our  study,   the  early  osteogenic  markers  genes  ALP  and  Col  Type   I  were  
upregulated  when  the  cells  were  stimulated  with  BMP2.      BMP2  in  synergy  with  
dexamethasone  (a  traditional  osteogenic  inducer)  upregulated  the  osteogenic  
differentiation   in   human   bone   marrow   stem   cells   [40].      In   our   study,   the  
enhanced  expressions  various  osteogenic  markers  of  HGMSCs  induced  with  
BMP2   was   also   in   the   presence   of   Dexamethasone.   Additionally,   BMP2  
enhanced  the  early  osteogenic  marker  gene  expression  in  both  2-­D  cultures  as  
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well  as  3-­D  cultures.  There  was  a  significant  increase  by  1.3,  1.5  and  2  folds  in  
50,100  and  200ng/ml  concentrations  respectively  when  HGMSCs  cultured   in  
PuramatrixTM  hydrogel  (3-­D).  The  enhancement  is  dose  dependent  manner  and  
much  higher  comparative  to  2  D  cultures.  Chen  et  al  [41]  conducted  a  detailed  
study   on   the   effects   of   periodic   heat   shock   on   hMSCs   and   reported   an  
upregulation   of   ALP   activity.   In   our   study,   although   we   have   not  measured  
activity   of   ALP,   our   results   showed   ALP   gene   upregulation.   RunX2   is   the  
earliest  transcription  factor  expressed  during  osteogenic  differentiation.  In  the  
presence  of  BMP2,  the  expression  of  RUNX2  was  found  to  be  comparable  in  
both  2  D  cultures  and  in  and  3  D  cultures.      It  is  interesting  to  note  that  the  study  
by  Chen  et  al.  demonstrated  the  inhibition  of  RUNX2  expression  when  the  cells  
were   induced   with   heat   shock.   Nevertheless,   the   cells   embedded   in  
PuramatrixTM  during  differentiation  showed  significant  increase  when  compared  
to   the  undifferentiated  cells.  Although  we   found  a  significant   increase   in   the  
expressions  of  RUNX2  and  collagen  gens  compared  to  the  osteogenic  medium,  
the  effect  was  similar  in  2-­D  and  3-­D  cultures.  It  may  be  attributed  to  the  fact  
that  matrix   stiffness   and   elasticity   of   the  material   could   affect   the   stem   cell  
differentiation  [42]  .    
Mineralization   is   a   hallmark   for   osteogenic   differentiation.   In   our   study,   we  
identified  profound   increase   in   the  mineralization  process  when  cells   treated  
with   BMP2.   The   effect   was   significant   in   the   cells   treated   with   100   and  
200ng/ml.  This  data  is  in  agreement  with  many  other  studies  [43,  44].  Our  study  
revealed   that   BMP2   induced   osteogenic   differentiation   and   hastened   the  
mineralization  process,  particularly  in  the  200ng/ml  dose  but  not  the  100ng/ml  
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dose.  This  could  be  due  to  the  potential  for  high  bath-­to-­bath  variability  between  
the   two   samples,   although   the   experiments   were   performed   under   similar  
conditions.    
  We  further  investigated  the  effect  of  delivery  method  whether  the  osteogenic  
differentiation  pattern  depends  on  the  type  of  delivery  of  growth  factor.  Overall  
results  of  our  study  demonstrated  that  the  application  of  osteoconductive  agent  
rhBMP2,   stimulated   the   osteogenic   differentiation   regardless   of   the   delivery  
method  that  was  used  in  this  study.  However,  BMP2  entrapped  in  PuramatrixTM  
showed   higher   ALP   expression   at   100ng/ml   compared   to   200ng/ml  
concentration.  In  the  present  study,  in  the  solubilized  method,  the  BMP2  was  
added   in   the  culture  medium  to   the  PuramatrixTM  encapsulated  HGMSCs  on  
every   other   day   which   resulted   in   using   high   amount   of   BMP2   than   the  
encapsulated  method.   It   is   interesting   to   note   that   the   upregulation   of   gene  
expression  of  osteogenic  markers  was  not  significantly  different  between  these  
two   groups.      Conventional   methods   of   administering   BMP2   in   the   culture  
medium  might  be  homogeneous,  however,   in  this  method  only  small  amount  
reaches  to  the  cellular  micro  domains  related  to  biological  signaling  pathways  
because  of  Brownian  motion  of  BMP-­2  released  from  a  matrix  utilizing  a  protein  
delivery  system  could  efficiently  bind  to  the  receptor  site  [45-­47].      
4.2  Conclusions: 
Mesenchymal  stem  cells  are  a  potential  stem  cell  based  strategy  for  the  repair  
of   the  craniofacial  region.  The  mesenchymal  stem  cells  derived  from  gingiva  
are  a  promising  cell  source  as  they  originate  from  neural  crest  region,  which  is  
responsible  for  craniofacial  development.  This  is  the  first  comprehensive  study  
  42 
to  investigate  the  effect  of  BMP2  in  three  different  culture  conditions.  Our  overall  
results   indicated   that   BMP2   enhanced   HGMSCs   osteogenic   differentiation  
ability   in   all   culture   conditions.   However,   the   effect   of   BMP2   is   significantly  
higher  in  the  cells  cultured  in  3-­D  environment  compared  to  2-­D  cultures.   Thus  
this  study  revealed  that  the  combination  of  osteogenic  gingival  stem  cells  and  
osteoinductive  BMP2  in  an  osteoconductive  PuramatrixTM  hydrogel  might  be  a  
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5.  RAW  DATA:  
  
      Gene  expression  studies  -­  Monolayer  culture  and  HGMSCS  with  PuramatrixTM  
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